Sanofi

News

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan

News

Sanofi drops lung cancer ADC tusamitamab ravtansine

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung

News

Sanofi abandons Maze Pompe deal after FTC lawsuit

Signs that the Federal Trade Commission (FTC) in the US may be softening its stance on pharma deals seem to have been misread, as the regulator has now sued to block Sanof

News

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo

News

Sanofi says new drugs can add €10bn to sales by 2030

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of th

News

Merck pummelled as MS hope evobrutinib dies in phase 3

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

Sanofi drops lung cancer ADC tusamitamab ravtansine

Sanofi abandons Maze Pompe deal after FTC lawsuit

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi says new drugs can add €10bn to sales by 2030

Merck pummelled as MS hope evobrutinib dies in phase 3

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Sanofi

Editor's Picks